CD163+ TAM, which have similar properties to M2 macrophages, are associated with an immunosuppressive microenvironment and unfavorable clinical outcomes in breast, bladder, ovarian, gastric, and prostate cancers (47–49). This evidence concerns the gene CD163 and prostate cancer.